Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 209

1.

Inhibition of protein disulfide isomerase in glioblastoma causes marked downregulation of DNA repair and DNA damage response genes.

Xu S, Liu Y, Yang K, Wang H, Shergalis A, Kyani A, Bankhead A 3rd, Tamura S, Yang S, Wang X, Wang CC, Rehemtulla A, Ljungman M, Neamati N.

Theranostics. 2019 Apr 12;9(8):2282-2298. doi: 10.7150/thno.30621. eCollection 2019.

2.

Activation of the Unfolded Protein Response via Inhibition of Protein Disulfide Isomerase Decreases the Capacity for DNA Repair to Sensitize Glioblastoma to Radiotherapy.

Liu Y, Ji W, Shergalis A, Xu J, Delaney AM, Calcaterra A, Pal A, Ljungman M, Neamati N, Rehemtulla A.

Cancer Res. 2019 Jun 1;79(11):2923-2932. doi: 10.1158/0008-5472.CAN-18-2540. Epub 2019 Apr 17.

PMID:
30996048
3.

A novel reporter for real-time, quantitative imaging of AKT-directed K63-poly-ubiquitination in living cells.

Nyati S, Chaudhry N, Chatur A, Gregg BS, Kimmel L, Khare D, Basrur V, Ray D, Rehemtulla A.

Oncotarget. 2018 Jan 25;9(13):11083-11099. doi: 10.18632/oncotarget.24323. eCollection 2018 Feb 16.

4.

Double-blind placebo-controlled multicenter phase II trial to evaluate D-methionine in preventing/reducing oral mucositis induced by radiation and chemotherapy for head and neck cancer.

Hamstra DA, Lee KC, Eisbruch A, Sunkara P, Borgonha S, Phillip B, Campbell KCM, Ross BD, Rehemtulla A.

Head Neck. 2018 Jul;40(7):1375-1388. doi: 10.1002/hed.25115. Epub 2018 Feb 23.

PMID:
29473247
5.

Imaging Proteolytic Activities in Mouse Models of Cancer.

Pal A, Rehemtulla A.

Methods Mol Biol. 2018;1731:247-260. doi: 10.1007/978-1-4939-7595-2_22.

6.

Quantitative and Dynamic Imaging of ATM Kinase Activity by Bioluminescence Imaging.

Nyati S, Young G, Ross BD, Rehemtulla A.

Methods Mol Biol. 2017;1599:97-111. doi: 10.1007/978-1-4939-6955-5_8.

7.

Quantitative and Dynamic Imaging of ATM Kinase Activity.

Nyati S, Young G, Ross BD, Rehemtulla A.

Methods Mol Biol. 2017;1596:131-145. doi: 10.1007/978-1-4939-6940-1_9.

8.

Noninvasive Bioluminescence Imaging of AKT Kinase Activity in Subcutaneous and Orthotopic NSCLC Xenografts: Correlation of AKT Activity with Tumor Growth Kinetics.

Suchowski K, Pöschinger T, Rehemtulla A, Stürzl M, Scheuer W.

Neoplasia. 2017 Apr;19(4):310-320. doi: 10.1016/j.neo.2017.02.005. Epub 2017 Mar 9.

9.

A Requirement for ZAK Kinase Activity in Canonical TGF-β Signaling.

Nyati S, Chator A, Schinske K, Gregg BS, Ross BD, Rehemtulla A.

Transl Oncol. 2016 Dec;9(6):473-481. doi: 10.1016/j.tranon.2016.09.010. Epub 2016 Oct 23.

10.

Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.

Ray P, Tan YS, Somnay V, Mehta R, Sitto M, Ahsan A, Nyati S, Naughton JP, Bridges A, Zhao L, Rehemtulla A, Lawrence TS, Ray D, Nyati MK.

Oncotarget. 2016 Oct 18;7(42):68597-68613. doi: 10.18632/oncotarget.11860.

11.

Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model.

Lemasson B, Wang H, Galbán S, Li Y, Zhu Y, Heist KA, Tsein C, Chenevert TL, Rehemtulla A, Galbán CJ, Holland EC, Ross BD.

Neoplasia. 2016 Feb;18(2):82-9. doi: 10.1016/j.neo.2015.11.014.

12.

Inducing Oncoprotein Degradation to Improve Targeted Cancer Therapy.

Ray D, Cuneo KC, Rehemtulla A, Lawrence TS, Nyati MK.

Neoplasia. 2015 Sep;17(9):697-703. doi: 10.1016/j.neo.2015.08.008. Review.

13.

Imaging Reporters for Proteasome Activity Identify Tumor- and Metastasis-Initiating Cells.

Stacer AC, Wang H, Fenner J, Dosch JS, Salomonnson A, Luker KE, Luker GD, Rehemtulla A, Ross BD.

Mol Imaging. 2015;14:414-28.

14.

Cancer stem cell marker phenotypes are reversible and functionally homogeneous in a preclinical model of pancreatic cancer.

Dosch JS, Ziemke EK, Shettigar A, Rehemtulla A, Sebolt-Leopold JS.

Cancer Res. 2015 Nov 1;75(21):4582-92. doi: 10.1158/0008-5472.CAN-14-2793. Epub 2015 Sep 10.

15.

Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer.

Brisset JC, Hoff BA, Chenevert TL, Jacobson JA, Boes JL, Galbán S, Rehemtulla A, Johnson TD, Pienta KJ, Galbán CJ, Meyer CR, Schakel T, Nicolay K, Alva AS, Hussain M, Ross BD.

PLoS One. 2015 Apr 10;10(4):e0123877. doi: 10.1371/journal.pone.0123877. eCollection 2015.

16.

Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy.

Galbán CJ, Ma B, Malyarenko D, Pickles MD, Heist K, Henry NL, Schott AF, Neal CH, Hylton NM, Rehemtulla A, Johnson TD, Meyer CR, Chenevert TL, Turnbull LW, Ross BD.

PLoS One. 2015 Mar 27;10(3):e0122151. doi: 10.1371/journal.pone.0122151. eCollection 2015.

17.

Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.

Van Dort ME, Galbán S, Wang H, Sebolt-Leopold J, Whitehead C, Hong H, Rehemtulla A, Ross BD.

Bioorg Med Chem. 2015 Apr 1;23(7):1386-94. doi: 10.1016/j.bmc.2015.02.053. Epub 2015 Mar 6.

18.

Phosphorylation of FADD by the kinase CK1α promotes KRASG12D-induced lung cancer.

Bowman BM, Sebolt KA, Hoff BA, Boes JL, Daniels DL, Heist KA, Galbán CJ, Patel RM, Zhang J, Beer DG, Ross BD, Rehemtulla A, Galbán S.

Sci Signal. 2015 Jan 27;8(361):ra9. doi: 10.1126/scisignal.2005607. Erratum in: Sci Signal. 2015 Mar 17;8(368):er3.

19.

The kinase activity of the Ser/Thr kinase BUB1 promotes TGF-β signaling.

Nyati S, Schinske-Sebolt K, Pitchiaya S, Chekhovskiy K, Chator A, Chaudhry N, Dosch J, Van Dort ME, Varambally S, Kumar-Sinha C, Nyati MK, Ray D, Walter NG, Yu H, Ross BD, Rehemtulla A.

Sci Signal. 2015 Jan 6;8(358):ra1. doi: 10.1126/scisignal.2005379.

20.

Parametric response mapping monitors temporal changes on lung CT scans in the subpopulations and intermediate outcome measures in COPD Study (SPIROMICS).

Boes JL, Hoff BA, Bule M, Johnson TD, Rehemtulla A, Chamberlain R, Hoffman EA, Kazerooni EA, Martinez FJ, Han MK, Ross BD, Galbán CJ.

Acad Radiol. 2015 Feb;22(2):186-94. doi: 10.1016/j.acra.2014.08.015. Epub 2014 Nov 4.

21.

A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer.

Cuneo KC, Chenevert TL, Ben-Josef E, Feng MU, Greenson JK, Hussain HK, Simeone DM, Schipper MJ, Anderson MA, Zalupski MM, Al-Hawary M, Galban CJ, Rehemtulla A, Feng FY, Lawrence TS, Ross BD.

Transl Oncol. 2014 Oct 24;7(5):644-9. doi: 10.1016/j.tranon.2014.07.005. eCollection 2014 Oct.

22.

Noninvasive imaging of apoptosis induced by adenovirus-mediated cancer gene therapy using a caspase-3 biosensor in living subjects.

Singh TD, Lee HW, Lee SW, Ha JH, Rehemtulla A, Ahn BC, Jeon YH, Lee J.

Mol Imaging. 2014;13. doi: 10.2310/7290.2014.00019.

PMID:
25022618
23.

Parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.

Galbán CJ, Boes JL, Bule M, Kitko CL, Couriel DR, Johnson TD, Lama V, Telenga ED, van den Berge M, Rehemtulla A, Kazerooni EA, Ponkowski MJ, Ross BD, Yanik GA.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1592-8. doi: 10.1016/j.bbmt.2014.06.014. Epub 2014 Jun 18.

24.

Image registration for quantitative parametric response mapping of cancer treatment response.

Boes JL, Hoff BA, Hylton N, Pickles MD, Turnbull LW, Schott AF, Rehemtulla A, Chamberlain R, Lemasson B, Chenevert TL, Galbán CJ, Meyer CR, Ross BD.

Transl Oncol. 2014 Feb 1;7(1):101-10. eCollection 2014 Feb.

25.

Evaluation of therapeutic effects of natural killer (NK) cell-based immunotherapy in mice using in vivo apoptosis bioimaging with a caspase-3 sensor.

Lee HW, Singh TD, Lee SW, Ha JH, Rehemtulla A, Ahn BC, Jeon YH, Lee J.

FASEB J. 2014 Jul;28(7):2932-41. doi: 10.1096/fj.13-243014. Epub 2014 Apr 15.

PMID:
24736413
26.

KRAS protein stability is regulated through SMURF2: UBCH5 complex-mediated β-TrCP1 degradation.

Shukla S, Allam US, Ahsan A, Chen G, Krishnamurthy PM, Marsh K, Rumschlag M, Shankar S, Whitehead C, Schipper M, Basrur V, Southworth DR, Chinnaiyan AM, Rehemtulla A, Beer DG, Lawrence TS, Nyati MK, Ray D.

Neoplasia. 2014 Feb;16(2):115-28. doi: 10.1593/neo.14184.

27.

Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts.

Ahsan A, Ramanand SG, Bergin IL, Zhao L, Whitehead CE, Rehemtulla A, Ray D, Pratt WB, Lawrence TS, Nyati MK.

Neoplasia. 2014 Feb;16(2):105-14. doi: 10.1593/neo.14182.

28.

Apoptosis imaging for monitoring DR5 antibody accumulation and pharmacodynamics in brain tumors noninvasively.

Weber TG, Osl F, Renner A, Pöschinger T, Galbán S, Rehemtulla A, Scheuer W.

Cancer Res. 2014 Apr 1;74(7):1913-23. doi: 10.1158/0008-5472.CAN-13-3001. Epub 2014 Feb 7.

29.

Impact of perfusion map analysis on early survival prediction accuracy in glioma patients.

Lemasson B, Chenevert TL, Lawrence TS, Tsien C, Sundgren PC, Meyer CR, Junck L, Boes J, Galbán S, Johnson TD, Rehemtulla A, Ross BD, Galbán CJ.

Transl Oncol. 2013 Dec 1;6(6):766-74. eCollection 2013 Dec 1.

30.
31.

NanoLuc reporter for dual luciferase imaging in living animals.

Stacer AC, Nyati S, Moudgil P, Iyengar R, Luker KE, Rehemtulla A, Luker GD.

Mol Imaging. 2013 Oct;12(7):1-13.

32.

Diffusion-Weighted MRI as a Biomarker of Tumor Radiation Treatment Response Heterogeneity: A Comparative Study of Whole-Volume Histogram Analysis versus Voxel-Based Functional Diffusion Map Analysis.

Lemasson B, Galbán CJ, Boes JL, Li Y, Zhu Y, Heist KA, Johnson TD, Chenevert TL, Galbán S, Rehemtulla A, Ross BD.

Transl Oncol. 2013 Oct 1;6(5):554-61. eCollection 2013.

34.

Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization.

Ahsan A, Ray D, Ramanand SG, Hegde A, Whitehead C, Rehemtulla A, Morishima Y, Pratt WB, Osawa Y, Lawrence TS, Nyati MK.

J Biol Chem. 2013 Sep 13;288(37):26879-86. doi: 10.1074/jbc.M113.492280. Epub 2013 Jul 29.

35.

Imaging proteolytic activity in live cells and animal models.

Galbán S, Jeon YH, Bowman BM, Stevenson J, Sebolt KA, Sharkey LM, Lafferty M, Hoff BA, Butler BL, Wigdal SS, Binkowski BF, Otto P, Zimmerman K, Vidugiris G, Encell LP, Fan F, Wood KV, Galbán CJ, Ross BD, Rehemtulla A.

PLoS One. 2013 Jun 11;8(6):e66248. doi: 10.1371/journal.pone.0066248. Print 2013.

36.

High-throughput screening identifies aclacinomycin as a radiosensitizer of EGFR-mutant non-small cell lung cancer.

Bennett DC, Charest J, Sebolt K, Lehrman M, Rehemtulla A, Contessa JN.

Transl Oncol. 2013 Jun 1;6(3):382-91. Print 2013 Jun.

37.

Molecular imaging of the ATM kinase activity.

Williams TM, Nyati S, Ross BD, Rehemtulla A.

Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):969-77. doi: 10.1016/j.ijrobp.2013.04.028. Epub 2013 May 29.

38.

DW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases.

Williams TM, Galbán S, Li F, Heist KA, Galbán CJ, Lawrence TS, Holland EC, Thomae TL, Chenevert TL, Rehemtulla A, Ross BD.

Transl Oncol. 2013 Apr;6(2):133-42. Epub 2013 Apr 1.

39.

Multimodality imaging of tumor and bone response in a mouse model of bony metastasis.

Hoff BA, Chughtai K, Jeon YH, Kozloff K, Galbán S, Rehemtulla A, Ross BD, Galbán CJ.

Transl Oncol. 2012 Dec;5(6):415-21. Epub 2012 Dec 1.

41.

Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma.

Wang H, Galbán S, Wu R, Bowman BM, Witte A, Vetter K, Galbán CJ, Ross BD, Cho KR, Rehemtulla A.

Clin Cancer Res. 2013 Jan 1;19(1):158-69. doi: 10.1158/1078-0432.CCR-12-2380. Epub 2012 Oct 24.

42.

Multimodal imaging of growth and rapamycin-induced regression of colonic adenomas in apc mutation-dependent mouse.

Miller SJ, Heist KA, Feng Y, Galbán CJ, Rehemtulla A, Ross BD, Fearon ER, Wang TD.

Transl Oncol. 2012 Oct;5(5):313-20. Epub 2012 Oct 1.

43.

Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression.

Galbán CJ, Han MK, Boes JL, Chughtai KA, Meyer CR, Johnson TD, Galbán S, Rehemtulla A, Kazerooni EA, Martinez FJ, Ross BD.

Nat Med. 2012 Nov;18(11):1711-5. doi: 10.1038/nm.2971. Epub 2012 Oct 7.

44.

Multi-system repeatability and reproducibility of apparent diffusion coefficient measurement using an ice-water phantom.

Malyarenko D, Galbán CJ, Londy FJ, Meyer CR, Johnson TD, Rehemtulla A, Ross BD, Chenevert TL.

J Magn Reson Imaging. 2013 May;37(5):1238-46. doi: 10.1002/jmri.23825. Epub 2012 Sep 28.

45.

Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.

Ahsan A, Ramanand SG, Whitehead C, Hiniker SM, Rehemtulla A, Pratt WB, Jolly S, Gouveia C, Truong K, Van Waes C, Ray D, Lawrence TS, Nyati MK.

Neoplasia. 2012 Aug;14(8):670-7.

46.

Predicting treatment efficacy via quantitative magnetic resonance imaging: a Bayesian joint model.

Wu J, Johnson TD, Galbán CJ, Chenevert TL, Meyer CR, Rehemtulla A, Hamstra DA, Ross BD.

J R Stat Soc Ser C Appl Stat. 2012 Jan 1;61(1):83-98. Epub 2011 Oct 10.

47.

Parametric response mapping of CT images provides early detection of local bone loss in a rat model of osteoporosis.

Hoff BA, Kozloff KM, Boes JL, Brisset JC, Galbán S, Van Poznak CH, Jacobson JA, Johnson TD, Meyer CR, Rehemtulla A, Ross BD, Galbán CJ.

Bone. 2012 Jul;51(1):78-84. doi: 10.1016/j.bone.2012.04.005. Epub 2012 Apr 17.

48.

DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.

Galbán S, Lemasson B, Williams TM, Li F, Heist KA, Johnson TD, Leopold JS, Chenevert TL, Lawrence TS, Rehemtulla A, Mikkelsen T, Holland EC, Galbán CJ, Ross BD.

PLoS One. 2012;7(4):e35857. doi: 10.1371/journal.pone.0035857. Epub 2012 Apr 20.

49.

Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer.

Williams TM, Flecha AR, Keller P, Ram A, Karnak D, Galbán S, Galbán CJ, Ross BD, Lawrence TS, Rehemtulla A, Sebolt-Leopold J.

Mol Cancer Ther. 2012 May;11(5):1193-202. doi: 10.1158/1535-7163.MCT-12-0098. Epub 2012 Mar 12.

50.

The interconnectedness of cancer cell signaling.

Rehemtulla A.

Neoplasia. 2011 Dec;13(12):1183-93.

Supplemental Content

Loading ...
Support Center